SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!
Novel Psychoactive Substances
Classification, Pharmacology and Toxicology
- 2nd Edition - September 6, 2021
- Editors: Paul I. Dargan, David M. Wood
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 8 7 8 8 - 3
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 9 0 3 0 - 2
Novel Psychoactive Substances: Classification, Pharmacology and Toxicology, Second Edition provides readers with a comprehensive examination on the classification, detection… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNovel Psychoactive Substances: Classification, Pharmacology and Toxicology, Second Edition provides readers with a comprehensive examination on the classification, detection, supply and availability of novel psychoactive substances, otherwise known as "legal highs." The book covers individual classes of novel psychoactive substances that have recently emerged onto the recreational drug scene and provides an overview of the pharmacology of the substance and a discussion of their associated acute and chronic harm and toxicity. This second edition addresses drugs new to the scene, with completely updated and revised chapters.
Written by international experts in the field, this multi-authored book is an essential reference for scientists, clinicians, academics, and regulatory and law enforcement professionals.
- Includes chapters written by international experts in the field
- Presents a comprehensive overview on the classification, detection, availability and supply of novel psychoactive substances, in addition to the pharmacology and toxicology associated with the substance
- Offers a single source for all interested parties working in this area, including scientists, academics, clinicians, law enforcement and regulatory agencies
- Provides a full treatment of novel psychoactive substances that have recently emerged onto the recreational drug scene, including amphetamines and the synthetic cannabinoid receptors in ‘spice’ and ‘K2’
Research scientists and academics in pharmacology and toxicology and biochemists, healthcare professionals, including physicians, nurses and paramedics, law enforcement and legislative authorities
- Cover Image
- Title Page
- Copyright
- Table of Contents
- Contributors
- Foreword
- Part I Background
- Chapter 1 Legal classification and international systems for monitoring and responding to novel psychoactive substances
- Abstract
- Statement on the United Kingdom
- Key methodological points
- Introduction
- Legal classification of novel (new) psychoactive substances
- European Union
- Current situation in Europe
- The future of novel psychoactive substances
- Conclusion
- Acknowledgments
- References
- Chapter 2 Availability and supply of novel psychoactive substances
- Abstract
- Background
- Novel psychoactive substance market
- NPS origins and market entry
- NPS market structure
- Products
- Conclusions
- Chapter 3 Prevalence of use of novel psychoactive substances
- Abstract
- Introduction
- General population surveys
- Summary and conclusions
- References
- Chapter 4 Pharmacological profiling of novel psychoactive substances
- Abstract
- Introduction
- Pharmacological profiling in vitro
- Pharmacological profiling in vivo
- Other profiling approaches
- Pharmacological targets
- References
- Chapter 5 Novel detection methods and data triangulation for novel psychoactive substances (NPS)
- Abstract
- Introduction
- Established monitoring systems for recreational drugs and NPS
- Surveys as indicators on the prevalence of NPS use to aid data triangulation
- Analytical strategies for new psychoactive substances to inform prevalence of use
- Emerging techniques of NPS detection within communities and geographical regions
- NPS detection and prevalence trends gained from emergency health care data
- Conclusion
- References
- Chapter 6 Social issues in the use of new psychoactive substances: Differentiated demand, displacement and adulteration
- Abstract
- Introduction
- Availability
- Prevalence in context: differentiated demand and social setting
- Understanding motivations: the displacement question
- Exploring social harms: legislative control and the supply of NPS
- Policy options in a changing world
- Historical stagnation, cyclical concerns and the NPS debate
- Conclusion
- References
- Chapter 7 General management of the patient with novel psychoactive substance toxicity
- Abstract
- Introduction
- Taking a recreational drug and NPS history
- Initial approach
- Assessment and management of specific drug/NPS related issues
- Investigation and analytical screening
- Known adulterants
- Assessment in prehospital settings and decision to transfer to ED
- Networking
- Discharge / further referral and treatment criteria
- References
- Chapter 8 Addiction and treatment of novel psychoactive substance dependence
- Abstract
- Introduction
- Psycho-social and aftercare interventions for the management of NPS dependence
- Dependence on depressant NPS (including dissociative drugs)
- Central nervous system stimulants
- Hallucinogens
- Synthetic cannabinoid receptor agonists (SCRAs)
- Concluding remarks
- References
- Part II Analytical techniques
- Chapter 9 Analytical techniques for the detection of novel psychoactive substances and their metabolites
- Abstract
- Introduction
- Analytical methods covering several classes of NPS
- Targeted methods for screening and/or quantification of NPS from specific drug classes
- Recommendations for setting up analytical methods for analysis of novel psychoactive substances
- References
- Part III Individual novel psychoactive substances
- Chapter 10 Synthetic amphetamine derivatives, benzofurans, and benzodifurans
- Abstract
- Synthetic amphetamine derivatives
- Monomethoxy derivatives
- Dimethoxy derivatives
- Trimethoxy derivatives
- Thiol-derivatives
- 4-Fluoroamphetamine
- Monomethyl derivatives
- Benzofurans and Benzodifurans
- References
- Chapter 11 Pharmacology and toxicology of N-Benzyl-phenylethylamines (25X-NBOMe) hallucinogens
- Abstract
- Introduction
- Pharmacology
- Acute toxicity
- Long-term harms and chronic toxicity
- Dependence and abuse potential
- Conclusions
- References
- Chapter 12 1-Benzylpiperazine and other piperazine-based stimulants
- Abstract
- Prevalence of use
- Pharmacology
- Pharmacokinetics
- Pharmacodynamics
- Toxicology
- Treatment
- References
- Chapter 13 Synthetic cathinones
- Abstract
- Introduction
- Mephedrone
- Pharmacokinetics
- Pharmacodynamics
- Acute toxicity
- Chronic toxicity
- Other cathinones
- References
- Chapter 14 Arylcyclohexamines
- Abstract
- Phenylcyclidine
- Pharmacology
- Prevalence of use
- Acute toxicity
- Chronic toxicity
- Dependence & abuse potential
- Ketamine
- Pharmacology
- Prevalence of use
- Acute toxicity
- Chronic toxicity
- Dependence and abuse potential
- Methoxetamine
- Pharmacology
- Prevalence of use
- Acute toxicity
- Chronic toxicity
- Dependence and abuse potential
- Other arylcyclohexamines
- Diarylethamines
- References
- Chapter 15 Synthetic cannabinoids (SC)
- Abstract
- Introduction
- Pharmacology
- Conclusions
- References
- Chapter 16 Novel synthetic opioids
- Introduction
- Physical and chemical properties
- Pharmacology
- Prevalence of use
- Toxicity
- Dependence and abuse potential
- References
- Chapter 17 Novel benzodiazepines
- Abstract
- Pharmacology
- Acute toxicity
- Deaths
- Chronic toxicity
- Dependence and abuse potential
- References
- Chapter 18 Tryptamines
- Abstract
- Tryptamines
- Pharmacology
- Prevalence of use
- Acute toxicity
- Conclusions
- References
- Index
- No. of pages: 554
- Language: English
- Edition: 2
- Published: September 6, 2021
- Imprint: Academic Press
- Hardback ISBN: 9780128187883
- eBook ISBN: 9780128190302
PD
Paul I. Dargan
Professor Dargan and Dr Wood are both expert advisors on novel psychoactive substances to expert bodies in the UK (Advisory Council on the Misuse of Drugs, ACMD), Europe (European Monitoring Centre for Drugs and Drug Addiction, EMCDDA) and Worldwide (United Nations Office on Drugs and Crime, UNODC). They run a clinical service managing patients with acute drug toxicity, and have a clinical and research interest in novel psychoactive substances. They publish widely in this field and have both been invited to give keynote lectures at International meetings on this topic.
Affiliations and expertise
Consultant Physician and Professor of Clinical Toxicology, London, UKDW
David M. Wood
David Wood is a Consultant Physician and Clinical Toxicologist at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
Affiliations and expertise
Consultant Physician and Clinical Toxicologist, Reader in Clinical Toxicology, London, UKRead Novel Psychoactive Substances on ScienceDirect